Tag: Avexitide
-
Why Blocking GLP-1 Can Prevent Hypoglycemia After Bariatric Surgery
This BP Science explainer examines the disease biology of post-bariatric hypoglycemia, how avexitide blocks GLP-1 receptor signaling, and how its mechanism compares with current off-label treatments and emerging GLP-1 receptor antagonists.
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.